Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
- Cytek Biosciences reported an earnings surprise of 80% and revenue of $44.86 million. - The stock has underperformed the market, losing about 30% since the beginning of the year. - Investors should watch for changes in earnings estimates and industry outlook. Price Impact Rating: bullish Impact Horizon Rating: short-term Type: Earnings
View signal analysis